The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Konverge 20 mg/5 mg film-coated tablets



Menarini International Operations Luxembourg S.A.PA0865/017/001

Main Information

Trade NameKonverge 20 mg/5 mg film-coated tablets
Active SubstancesOlmesartan medoxomil
Amlodipine
Dosage FormFilm-coated tablet
Licence HolderMenarini International Operations Luxembourg S.A.
Licence NumberPA0865/017/001

Group Information

ATC CodeC09DB Angiotensin II antagonists and calcium channel blockers
C09DB02 olmesartan medoxomil and amlodipine

Status

License statusAuthorised
Licence Issued19/06/2009
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back